Tuesday, January 17, 2006 11:11:14 AM
AP, Friday January 13, 2:05 pm ET
Nektar Shares Rise As Pfizer Buys Out World Rights to Exubera From Sanofi Aventis http://finance.yahoo.com/q/bc?s=NKTR&t=5d&l=off&z=m&q=l&c=
NEW YORK (AP) -- Shares of drug-delivery technology company Nektar Therapeutics jumped Friday after drug maker Pfizer Inc. said it would pay Sanofi Aventis SA $1.3 billion for global rights to the inhalable insulin the three companies developed.
Nektar shares rose $1.78, or 9.8 percent, to $19.89 in afternoon trading on the Nasdaq at more than seven times their average volume. Shares have traded between $13.32 and $21.52 over the past 52 weeks.
In a research note, investment firm Morgan Stanley said Pfizer's move shows that it is optimistic about the Food and Drug Administration's Jan. 27 decision due date for the product. The firm said the deal will not affect Nektar's 15 percent royalty from sales, but that the deal reflect Pfizer's commitment to the product.
The original due date for an FDA decision was Oct. 27, but the agency said it needed more time to review additional technical chemistry data on Exubera. In September, an FDA advisory panel recommended approval of the dry powder form of insulin that is inhaled rather than injected, but expressed safety concerns about some patients who experienced reduced lung function and coughing. Pfizer has promised to continue studying the drug's safety following approval.
Deutsche Bank agreed the action shows that Pfizer sees Exubera as a major driver for future growth, and expects positive near-term regulatory decisions in the United States and Europe.
The agreement settles legal action started by Pfizer in 2004 with the formation of Sanofi Aventis. Pfizer had originally been working on the product with Aventis, and Pfizer alleged that the merger had resulted in a change of control that violated the original contract.
Shares of Pfizer fell 5 cents to $24.53, and American depositary shares of Sanofi Aventis fell 3 cents to $46.93 on the New York Stock Exchange.
http://biz.yahoo.com/ap/060113/nektar_mover.html?.v=1
Recent NKTR News
- Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 • PR Newswire (US) • 09/25/2024 07:30:00 AM
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 09/03/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:15:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:15:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:14:28 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:13:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:03:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 07:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:20:09 PM
- Nektar Therapeutics Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/08/2024 08:15:00 PM
- Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets • PR Newswire (US) • 08/01/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:02:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 08:11:19 PM
- Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 • PR Newswire (US) • 06/12/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:42 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/06/2024 04:15:16 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/05/2024 09:30:37 PM
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 10:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/28/2024 08:51:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:14:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:13:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:12:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:25:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:22:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:14:49 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM